SBG003

About Sonoran Biosciences

Sonoran Biosciences is a Scottsdale-based biotech founded in 2018, targeting two major unmet needs in surgical care: postoperative pain and surgical site infection (SSI). The company's core technology is the SB Gel, a biomaterial platform for localized, sustained drug release. Its lead candidates are SBG004, a sustained-release local anesthetic for pain, and SBG003, a sustained-release antimicrobial for SSI prevention, with both programs in development and supported by NIH SBIR funding.

Therapeutic Areas